Region: North America

US trends surrounding four prominent IP finance insurance types

Featured in Special Report 2024 Q2: Money, money, money

28 June 2024

Executive summary

Featured in Special Report 2024 Q2: Money, money, money

28 June 2024

Around the world

Featured in Special Report 2024 Q2: Money, money, money

28 June 2024

Securing legal finance for patent monetisation

Featured in Special Report 2024 Q2: Money, money, money

28 June 2024

What drives business divorces and how to protect trade secrets during separations 

Gregory Brown, lawyer at Hill Ward Henderson, shares tips for handling soured corporate relationships and an unusual trade secret case 

27 June 2024

Patent eligibility question on verdict forms – a new opportunity for patent holders?

When juries answer the question about Alice’s “inventive concept” prong, patentees won 44% of the time and partially won another 11%

26 June 2024

Former AON IP Solutions CEO Lewis Lee launches new AI-fuelled analytics platform with Aon-acquired IP

Moat Metrics Inc offers a SaaS product enabling investors and decision-makers to understand more fully how IP is a business asset and wield that intelligence to build value

26 June 2024

WiLAN buying portfolios, striking licences in first year as private monetisation firm

On the anniversary of Canadian patent licensing firm WiLAN’s sale to private investors, CEO Andrew Parolin boasts of a very successful 12 months in an exclusive IAM interview

25 June 2024

Randomly assigned WDTX judges handle major patent motions differently to Judge Alan Albright

Docket Navigator data shows how randomly assigned Western District of Texas judges are ruling on IPR stays, convenience transfers, dismissal motions and summary judgment

24 June 2024

A closer look at the latest PTAB estoppel developments

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

As courts continue to shape and refine the metes and bounds of PTAB estoppel on subsequent invalidity challenges before the district courts and the USPTO, patent challengers should carefully consider their strategies for invalidating biotechnology and pharmaceutical patents.

24 June 2024

Unlock unlimited access to all IAM content